Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 proof-of-concept study of guselkumab in new-onset or relapsing giant cell arteritis
2020-000622-26Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in giant cell arteritis (GCA) comparing Guselkumab + glucocorticoid taper with Placebo + glucocorticoid taper (2 arms). Primary endpoint: Glucocorticoid-free remission at primary time point. Started Aug 2020; status: terminated.
02
Drugs
guselkumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2020-000622-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000622-26.